+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemostatic Agents Market - Forecast (2020 - 2025)

  • PDF Icon

    Report

  • 104 Pages
  • March 2020
  • Region: Global
  • IndustryARC
  • ID: 3786644
Hemostats are instruments used to reduce or halt bleeding during a surgery. These can be enabled by the use of smearing pressure, stitching the bleeding or using thermal energy devices. Hemostats generally are used to clot the blood during surgical procedures. Technical advancements have increased the usage of topical hemostatic agents in an extensive variety of surgical situations. Make it into a different sentence. New tissue sealants and hemostats in the market have addressed issue related to tissue contamination with previous sealants. How the new tissue sealants are addressing the previous sealant. New tissue sealants helps in reducing tissue contamination. Global hemostatic agents market is estimated to grow at a CAGR of 7.1% to reach $8,347.9m by 2022.

The report analyzes the hemostatic agents market by type, by treatment and by end user. The market by types covered in the report are thrombin, gelatin, collagen, oxidized regenerated, fibrin sealants and combination hemostats. Fibrin Sealants are estimated to be the fastest growing hemostatic agents during the forecast period 2020-2022. The hemostatic agents market is also segmented by treatment which includes cardio vascular, general surgery, digestive and neuro-surgery. This report highlights the end users of hemostatic agents such as hospitals, surgery centers and nursing homes. The report estimates the size of the global market in value terms ($million).

The report provides market size and forecast for APAC, Europe, Americas and RoW. A detailed qualitative analysis of the factors responsible to driving and restraining growth of the hemostatic agents market and future opportunities are provided in the report. The report profiles thirteen key players of the hemostatic agents market.

Sample Companies Profiled in this Report are:


  • Johnson & Johnson Services, Inc. (U.S.)

  • Baxter International Incorporation (U.S.)

  • C.R. Bard Incorporation (U.S.)

  • B.Braun Melsungen AG (Germany)

  • Advanced Medical Solutions Group (U.K.)

  • 10+.

Table of Contents

1. Hemostatic Agents Market Overview2. Hemostatic Agents Market Executive Summary
3. Hemostatic Agents Market Landscape
3.1. Market Share Analysis
3.2. Financial Analysis
3.3. End User Profiling
3.4. Product Benchmarking
3.5. Patent Analysis
4. Hemostatic Agents Market Forces
4.1. Market Drivers
4.2. Market Constraints & Challenges
4.3. Attractiveness of Hemostatic Agents Market
4.3.1. Power of Suppliers
4.3.2. Power of Buyers
4.3.3. Threat of Substitutes
4.3.4. Threat of New entrants
4.3.5. Degree of Competitive Rivalry
5. Hemostatic Agents Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Market Life Cycle Analysis
5.4. Pricing Analysis
6. Hemostatic Agents Market – By Type
6.1. Introduction
6.2. Thrombin Based Hemostats
6.3. Gelatin Based Hemostats
6.4. Collagen Based Hemostats
6.5. Oxidized Regenerated Cellulose Based Hemostats
6.6. Combination Hemostats
6.7. Fibrin Sealants
6.8. Others
7. Hemostatic Agents Market – By Treatment
7.1. Introduction
7.2. Cardiovascular
7.3. General Surgery
7.4. Digestive Surgery
7.5. Neurosurgery
7.6. Others
8. Hemostatic Agents Market – By End User
8.1. Introduction
8.2. Hospitals
8.3. Surgery Centers
8.4. Nursing Homes
8.5. Others
9. Hemostatic Agents Market -Geographic Analysis
9.1. Introduction
9.2. Americas
9.2.1. U.S
9.2.2. Canada
9.2.3. Mexico
9.2.4. Brazil
9.2.5. Rest of Americas
9.3. Europe
9.3.1. U.K.
9.3.2. Germany
9.3.3. France
9.3.4. Italy
9.3.5. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia & New Zealand
9.4.5. South Korea
9.4.6. Rest of APAC
9.5. RoW
9.5.1. Africa
9.5.2. Middle East
10. Hemostatic Agents Market Entropy
11. Hemostatic Agents Market Company Profiles
11.1. Baxter International Incorporation (U.S.)
11.2. C.R. Bard Incorporation (U.S.)
11.3. B.Braun Melsungen AG (Germany)
11.4. Integra Life Sciences Corporation (U.S.)
11.5. Equimedical (Netherlands)
11.6. Marine Polymer Technologies (U.S.)
11.7. Gelita GmbH (Germany)
11.8. Johnson and Johnson Services Inc (U.S.)
11.9. Pfizer Inc (U.S.)
11.10. Advanced Medical Solutions Group (U.K.)
11.11. Vascular Solutions, Inc (U.S.)
11.12. Z-Medica LLC (U.S.)
11.13. Mallinckrodt Plc (U.S.)
12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Bibliography
12.5. Compilation of Expert Insights
12.6. Disclaimer

Methodology

Loading
LOADING...